Sustained Management of Essential High Blood Pressure

Losartan is primarily used for managing essential hypertension, addressing the continuous, often symptoms that create noticeable physiological strain caused by elevated systemic blood pressure. This consistent management contributes to foundational cardiovascular protection and plays a role in managing the chronic risk associated with circulatory pressure overload on the heart and arteries.

Protection Against Complications

The medication supports specialized protective benefits against symptoms linked to organ-specific functional stress, managing findings like abnormal heart wall thickening known as Left Ventricular Hypertrophy (LVH), and helps address objective clinical findings such as proteinuria (protein leakage).

It assists by providing a therapeutic option for patients who require therapeutic action in this area but have demonstrated difficulty tolerating other agents. This usage supports the patient during difficult episodes by addressing risk factors related to major adverse events, including stroke.

Quick Fact: Support for Physiological Strain
Losartan helps address symptoms that create noticeable physiological strain by managing sustained elevated blood pressure, which contributes to easing the overall systemic burden.

Regulatory References

1. Losartan: MedlinePlus Drug Information

Eligibility Map: Who Can and Cannot Use Losartan (Lo) — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults are eligible for all approved uses. Pediatric patients aged 6 years and older are eligible for the treatment of hypertension only.

Populations for whom use is not recommended (if applicable):

• Pediatric patients under 6 years of age and those with a Glomerular Filtration Rate (GFR) <30 mL/min/1.73 m^2 are not recommended for use. Use is also not recommended while breastfeeding.

Populations for whom use is contraindicated:

• Women in the second and third trimesters of pregnancy; patients with known hypersensitivity to Losartan; and individuals with diabetes or renal impairment receiving aliskiren. Severe hepatic impairment is also a formal contraindication in some regions.

---

Age-Related Eligibility Rules

Pediatric eligibility is restricted to patients ge 6 years old for hypertension; safety has not been established below this age threshold. Geriatric patients may be used with no significant differences in efficacy noted.

Condition-Specific Eligibility Rules

Patients with mild-to-moderate hepatic impairment may be eligible but require conditional use. Individuals with volume or salt depletion must have the condition corrected or require a reduced starting approach.

Pregnancy and Lactation Eligibility Status (if explicitly documented)

Pregnancy (2nd and 3rd Trimesters) is contraindicated. Lactation is not recommended.

Eligibility-Related Restrictions

The labeled benefit for stroke risk reduction in patients with hypertension and Left Ventricular Hypertrophy (LVH) does not apply to Black patients.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Includes Contraindicated, Not Recommended, and Conditional Use classifications.

Regulatory basis (EMA / FDA / etc.): Derived directly from government-approved prescribing information.

Eligibility-context constraints (as defined in official documents): Constraints include specific trimester status, age threshold, and specific organ impairment severity.

Resulting Eligibility Structure

Official eligibility statements:

• Losartan is contraindicated in women who are in the second and third trimesters of pregnancy.
• Use is not established for non-hypertensive indications in children.
• The medicine is contraindicated for diabetic or renally impaired patients receiving aliskiren.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define eligibility for Losartan by establishing specific populations who are allowed to use the medicine, those for whom use is absolutely prohibited (contraindications), and those who require conditional use based on their underlying physiological state or age.

Losartan's officially documented interaction profile is governed by effects that alter body chemistry (pharmacodynamic) and those that modify drug levels (pharmacokinetic).

Pharmacodynamic Interactions and Restrictions

A major restriction involves Aliskiren, which is formally contraindicated for co-administration in patients with Type 2 Diabetes Mellitus or Renal Impairment due to the severe, increased risk of renal impairment, hyperkalemia, and hypotension. Co-administration with Potassium-sparing Diuretics or Potassium Supplements is restricted due to the additive risk of hyperkalemia.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are associated with an increased risk of renal impairment and can reduce the intended antihypertensive effect. The drug may also decrease the renal clearance of Lithium, leading to an increased risk of toxicity. Consumption of Alcohol may result in additive blood pressure lowering effects.

Pharmacokinetic Interactions

Quantified exposure changes are documented for several medicines. Fluconazole, a CYP2C9 inhibitor, increases the systemic exposure (AUC) of Losartan by approximately 70%. Conversely, inducers like Rifampin decrease the exposure of the active metabolite (E-3174) by approximately 40%. Patients with hepatic impairment are noted in regulatory information to have significantly increased Losartan plasma concentrations, suggesting a heightened sensitivity to these exposure-altering interactions.

How Lo Works: The Pharmacodynamic Mechanism

The primary mechanism involves the metabolism of the parent drug into its highly active form, Desloratadine. This metabolite functions as a selective inverse agonist at the peripheral Histamine H1 Receptor ( H1 R), physically blocking histamine from binding and maintaining the receptor in an inactive configuration. This molecular action prevents the H1 R-mediated signaling cascade, resulting in a physiological reduction in vascular permeability and vasodilation in peripheral tissues.

Beyond receptor blockade, the drug engages secondary, non- H1 R mechanisms by acting as an inhibitor of intracellular enzymes, including Syk and TAK1 kinases. This interference suppresses the activity of genetic regulators like NF-kappa B, thereby limiting the cell's ability to produce and release secondary inflammatory mediators such as cytokines and chemokines. The active metabolite's long half-life contributes to a sustained duration of the resulting physiological effects, while its low affinity for central nervous system H1 R subtypes restricts its action predominantly to peripheral systems.

How Losartan is Used

Losartan potassium (Lo) is administered solely through the oral route, typically as a film-coated tablet in strengths of 25 mg, 50 mg, or 100 mg. For individuals who cannot swallow tablets, an official extemporaneously prepared oral suspension (2.5 mg/mL) may be used as an alternative form.

---

Standard Dosing and Administration Schedule

Losartan is usually taken once daily (qDay). However, to optimize blood pressure control, the total daily amount may be administered as a divided dose (twice daily). It can be taken with or without food and should be ingested at approximately the same time each day for consistency. Treatment for chronic conditions like hypertension is a long-term plan, and the maximal effect on blood pressure may not be fully apparent until three to six weeks of consistent administration.

---

Official Dosing Ranges

Clinical Context	Usual Starting Dose	Maximum Daily Dose
Most Adults (Hypertension)	50 mg once daily	100 mg once daily
Volume Depleted / Hepatic Impairment	25 mg once daily	100 mg once daily
Pediatric (Children ge 6 years)	0.7 mg/kg once daily	100 mg total daily dose

---

Usage Adjustments and Missed Doses

A lower starting dose of 25 mg once daily is used for patients with hepatic impairment (liver dysfunction) or those with suspected volume depletion. For adults with renal impairment, including those on dialysis, no initial dose modification is typically required. If a dose is missed, it should not be taken at the next scheduled time, nor should the dose be doubled; the patient should simply resume the regular schedule.

Research Evidence / Overview of Studies for Lo

Evidence for Use in Managing Essential High Blood Pressure

A significant portion of the research supporting Losartan (Lo) was conducted using Randomized Controlled Trials (RCTs), where study participants were assigned to receive Losartan, a placebo (an inactive treatment), or a pre-selected antihypertensive medicine. These trials were designed to examine outcomes related to systemic or functional imbalance associated with high blood pressure. Researchers monitored and measured the change in blood pressure readings, such as systolic and diastolic pressure, over defined time intervals.

Studies examined whether Losartan was associated with changes in blood pressure readings in adults with essential hypertension. Research also monitored the percentage of patients who met a pre-specified blood pressure measurement goal. The available evidence contributes to the broader evidence landscape regarding blood pressure monitoring.

Research on High Blood Pressure with Heart Wall Thickening (Left Ventricular Hypertrophy, LVH)

This section summarizes large-scale, long-term RCTs that specifically evaluated Losartan in patients who had high blood pressure and objective signs of heart wall thickening (LVH). These studies explored how symptoms evolved in the observed populations, which were typically older adults presenting with specific risk factors.

The research examined high-level endpoints, which are outcomes monitoring physiological strain or stress, such as the occurrence of stroke, cardiovascular-related death, and non-fatal heart attacks. Studies also monitored changes in the thickness of the heart wall, known as the Left Ventricular Mass Index. Trials reported patterns in stroke incidence measurements between the two assigned study groups.

Studies for Kidney Involvement in Type 2 Diabetes

Key research for this indication includes large, multinational, placebo-controlled RCTs that examined Losartan in patients who had both Type 2 Diabetes and objective evidence of kidney involvement (nephropathy). Studies monitored a composite renal endpoint, which combined several clinical events related to kidney health. Findings highlight changes measured during the study period related to the amount of protein excretion in the urine.

Research Gaps and Areas of Uncertainty for Losartan

While a significant amount of data exists, certain aspects of Losartan's research base remain insufficient or are still being explored. The evidence quality varies across studies regarding a full comparison against all similar drugs in its class; many trials focused on comparison with pre-selected comparator medicines. Data for certain groups, such as those with Type 1 diabetes and nephropathy, remain insufficient. Commentaries noted that limitations existed related to the definition of certain primary endpoints, and long-term effects are not fully established in all minor indications.

How to Store and Dispose of Losartan (Lo) Tablets

Official labeling mandates specific storage conditions to maintain the stability of Losartan potassium tablets. The medicine must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). The tablets must be protected from freezing, excess heat, light, and moisture.

The medication must be kept in the original, tightly closed container and stored out of the sight and reach of children.

For disposal, unused or expired Losartan should not be flushed down the toilet or poured down a drain. Patients should prioritize using a drug take-back program or follow official household disposal guidance for unused medicines.